| Autor: |
Kinuko, Ohneda, Masahiro, Hiratsuka, Hiroshi, Kawame, Fuji, Nagami, Yoichi, Suzuki, Kichiya, Suzuki, Akira, Uruno, Mika, Sakurai-Yageta, Yohei, Hamanaka, Makiko, Taira, Soichi, Ogishima, Shinichi, Kuriyama, Atsushi, Hozawa, Hiroaki, Tomita, Naoko, Minegishi, Junichi, Sugawara, Inaho, Danjoh, Tomohiro, Nakamura, Tomoko, Kobayashi, Yumi, Yamaguchi-Kabata, Shu, Tadaka, Taku, Obara, Eiji, Hishimuma, Nariyasu, Mano, Masaki, Matsuura, Yuji, Sato, Masateru, Nakasone, Yohei, Honkura, Jun, Suzuki, Yukio, Katori, Yoichi, Kakuta, Atsushi, Masamune, Yoko, Aoki, Masaharu, Nakayama, Shigeo, Kure, Kengo, Kinoshita, Nobuo, Fuse, Masayuki, Yamamoto |
| Rok vydání: |
2021 |
| Zdroj: |
JMA journal. 5(2) |
| ISSN: |
2433-3298 |
| Popis: |
Pharmacogenomic (PGx) testing results provide valuable information on drug selection and appropriate dosing, maximization of efficacy, and minimization of adverse effects. Although the number of large-scale, next-generation-sequencing-based PGx studies has recently increased, little is known about the risks and benefits of returning PGx results to ostensibly healthy individuals in research settings.Single-nucleotide variants of three actionable PGx genes, namely,Whereas the majority of participants were unfamiliar with the term PGx, and none had undergone PGx testing before the study, more than 80% of the participants felt that they could acquire basic PGx knowledge sufficient to understand their genomic results and were satisfied with their potential benefit and use in future prescriptions. On the other hand, some felt that the PGx concepts or terminology was difficult to fully understand and suggested that in-person return of the results was desirable.These results collectively suggest possible benefits of returning preemptive PGx information to ostensibly healthy cohort participants in a research setting. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
